Skip to content

    Cohance Life

    COHANCEGood
    Healthcare·28 May 2025
    Management Summary

    Cohance Lifesciences (formerly Suven Pharma) completed its formal merger and rebranding, positioning itself as a technology-led CDMO platform. While FY25 was a foundational year of integration and strategic acquisitions (NJ Bio, Sapala), the company delivered steady 9% growth. Management is guiding for an acceleration in FY26, targeting double-digit revenue growth despite temporary margin pressure from ongoing investments.

    Highlights

    6

    • Full year FY25 revenue reached $335 million with a 9% YoY growth rate.

    • FY25 EBITDA margin stood at 34%, though Q4 adjusted EBITDA margin dipped to 31.3% due to business mix and acquisition integration.

    • Pharma CDMO segment was the primary growth driver, expanding 18% YoY.

    • Commercial molecules increased to 16 (from 10) and the Phase III pipeline expanded to 9 molecules (from 2).

    • Generated Rs. 3.6 billion in free cash flow, maintaining a cash balance of Rs. 2.9 billion.

    • Management set a long-term vision to become a $1 billion revenue company by 2030.

    What Changed1

    vs Q1 FY26

    Guidance items5 → 4 (-1)
    Key financials

    Metrics

    5

    Periods

    2

    Headline

    3
    • Revenue
      335 Mn
      YoY+9%
    • EBITDA Margin
      34%
    • Free Cash Flow
      $3.6B

    Q4

    2
    • Revenue Growth
      20%
      YoY+20%
    • Adjusted EBITDA Margin
      31.3%

    Segment breakdown

    Pharma CDMO
    18% Revenue Growth9 molecules Phase-3 Pipeline
    API+
    9% Revenue Growth9 products Product Validations
    Specialty Chemicals
    0 sequential recovery Performance Trend
    List

    Guidance & targets

    3
    CategoryTargetPriority
    Revenue
    Revenue Growth
    in the teens
    		Medium
    Margin
    EBITDA Margin
    low 30s
    		High
    Capex
    Total CAPEX
    Rs. 350 crore
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Inventory De-stocking

    Customers for a few commercial molecules are pausing orders for FY26 to adjust inventory levels. — Management acknowledged

    medium

    Lumpy Nature of CDMO Industry

    Quarterly performance can be volatile due to shipment timings; annual trends are better indicators. — Management acknowledged

    low

    Lower Margin from New Acquisitions

    NJ Bio currently operates at a lower EBITDA margin than the group average, dragging down consolidated margins during integration. — Both acknowledged

    medium

    Areas of Evasion(2)

    • Specific therapeutic categories for the 9 Phase-3 molecules (cited CDAs).
    • Specific revenue growth percentage beyond 'teens'.

    Q&A highlights

    3

    “Rationale for acquisition of Sapala and NJ Bio... we wanted to expand our capabilities on technology and both ADCs and Oligo are fast growing capabilities... investment in these capabilities have allowed us to enter and expand our tab.”

    Explains the strategic shift toward high-growth, complex modalities like Antibody Drug Conjugates (ADCs) and Oligonucleotides.

    asked by Mehul Panjuani

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Transformation into a Global CDMO Platform

    Cohance Lifesciences has successfully transitioned from Suven Pharmaceuticals into an integrated technology-led CDMO. The company has institutionalized three core business units: Pharma CDMO, API+, and Specialty Chemicals. Management highlighted that FY25 was a foundational year, focusing on the integration of NJ Bio and Sapala Organics to bolster capabilities in high-growth modalities like ADCs and oligonucleotides.

    02

    Pharma CDMO Pipeline Shows Significant Expansion

    The Pharma CDMO segment grew 18% YoY, driven by a substantial increase in the project pipeline. Commercial molecules grew from 10 to 16, while the late-stage Phase III pipeline expanded from 2 to 9 molecules. Management expects one major product with four intermediates to enter commercial production in FY26, providing a clear path for near-term growth.

    03

    Temporary Margin Headwinds in FY26

    Management guided for EBITDA margins in the 'low 30s' for FY26, a step down from the 34% achieved in FY25. This compression is attributed to the integration of NJ Bio (which has lower margins), investments in talent and infrastructure ahead of the growth curve, and inventory de-stocking by certain customers. However, the mid-term target remains in the mid-30s as operating leverage kicks in.

    04

    Specialty Chemicals Recovery Underway

    After a challenging first half of FY25 due to macro-environmental factors, the Specialty Chemicals segment saw a sequential recovery in Q4. Management established a dedicated business unit for this segment and expects it to be one of the 'three engines of growth' firing in FY26, supported by increased customer interactions and new project RFQs.

    05

    Aggressive CAPEX and M&A Strategy

    The company plans to spend approximately Rs. 350 crore on CAPEX in FY26, primarily for NJ Bio's expanded bioconjugation facility in the U.S. and GMP capabilities at Sapala. Management remains open to a 'programmatic M&A approach' to continue scaling niche capabilities, supported by a strong net cash balance sheet and Rs. 3.6 billion in annual free cash flow.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.